These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 15246912)

  • 21. Inhibition of big ET-1-induced pressor response by an orally active dual inhibitor of endothelin-converting enzyme and neutral endopeptidase 24.11.
    Trapani AJ; De Lombaert S; Kuzmich S; Jeng AY
    J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S69-71. PubMed ID: 8587471
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design and synthesis of potent, selective inhibitors of endothelin-converting enzyme.
    Wallace EM; Moliterni JA; Moskal MA; Neubert AD; Marcopulos N; Stamford LB; Trapani AJ; Savage P; Chou M; Jeng AY
    J Med Chem; 1998 Apr; 41(9):1513-23. PubMed ID: 9554884
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Benzofused macrocyclic lactams as triple inhibitors of endothelin-converting enzyme, neutral endopeptidase 24.11, and angiotensin-converting enzyme.
    Ksander GM; Savage P; Trapani AJ; Balwierczak JL; Jeng AY
    J Cardiovasc Pharmacol; 1998; 31 Suppl 1():S71-3. PubMed ID: 9595404
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacological profile of a non-peptidic dual inhibitor of neutral endopeptidase 24.11 and endothelin-converting enzyme.
    De Lombaert S; Ghai RD; Jeng AY; Trapani AJ; Webb RL
    Biochem Biophys Res Commun; 1994 Oct; 204(1):407-12. PubMed ID: 7945387
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modulation of functionally active endothelin-converting enzyme by chronic neutral endopeptidase inhibition in experimental atherosclerosis.
    Grantham JA; Schirger JA; Wennberg PW; Sandberg S; Heublein DM; Subkowski T; Burnett JC
    Circulation; 2000 Apr; 101(16):1976-81. PubMed ID: 10779465
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect on blood pressure of combined inhibition of endothelin-converting enzyme and neutral endopeptidase with daglutril in patients with type 2 diabetes who have albuminuria: a randomised, crossover, double-blind, placebo-controlled trial.
    Parvanova A; van der Meer IM; Iliev I; Perna A; Gaspari F; Trevisan R; Bossi A; Remuzzi G; Benigni A; Ruggenenti P;
    Lancet Diabetes Endocrinol; 2013 Sep; 1(1):19-27. PubMed ID: 24622263
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacological properties of CGS 35066, a potent and selective endothelin-converting enzyme inhibitor, in conscious rats.
    Trapani AJ; Beil ME; Bruseo CW; De Lombaert S; Jeng AY
    J Cardiovasc Pharmacol; 2000 Nov; 36(5 Suppl 1):S40-3. PubMed ID: 11078331
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Renoprotective effects of combined endothelin-converting enzyme/neutral endopeptidase inhibitor SLV338 in acute and chronic experimental renal damage.
    Sharkovska Y; Kalk P; von Websky K; Relle K; Pfab T; Alter M; Fischer Y; Hocher B
    Clin Lab; 2011; 57(7-8):507-15. PubMed ID: 21888014
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The peptidase inhibitor CGS-26303 increases endothelin converting enzyme-1 expression in endothelial cells through accumulation of big endothelin-1.
    Raoch V; Martinez-Miguel P; Arribas-Gomez I; Rodriguez-Puyol M; Rodriguez-Puyol D; Lopez-Ongil S
    Br J Pharmacol; 2007 Oct; 152(3):313-22. PubMed ID: 17643133
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential expression of neutral endopeptidase-24.11 (neprilysin) and endothelin-converting enzyme in human prostate cancer cell lines.
    Usmani BA; Harden B; Maitland NJ; Turner AJ
    Clin Sci (Lond); 2002 Aug; 103 Suppl 48():314S-317S. PubMed ID: 12193112
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dual endothelin-converting enzyme/neutral endopeptidase inhibition: a novel treatment for renovascular hypertension beyond blood pressure lowering?
    Dhaun N; Webb DJ
    Hypertension; 2011 Apr; 57(4):667-9. PubMed ID: 21339473
    [No Abstract]   [Full Text] [Related]  

  • 32. Attenuation of Doxorubicin-induced cardiomyopathy by endothelin-converting enzyme-1 ablation through prevention of mitochondrial biogenesis impairment.
    Miyagawa K; Emoto N; Widyantoro B; Nakayama K; Yagi K; Rikitake Y; Suzuki T; Hirata K
    Hypertension; 2010 Mar; 55(3):738-46. PubMed ID: 20101000
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of endothelin-converting enzyme, chymase and neutral endopeptidase in the processing of big ET-1, ET-1(1-21) and ET-1(1-31) in the trachea of allergic mice.
    De Campo BA; Goldie RG; Jeng AY; Henry PJ
    Clin Sci (Lond); 2002 Aug; 103 Suppl 48():353S-356S. PubMed ID: 12193121
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SLV-306. Solvay.
    Tabrizchi R
    Curr Opin Investig Drugs; 2003 Mar; 4(3):329-32. PubMed ID: 12735234
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Endothelin-converting enzyme inhibitors: current status and perspectives.
    Löffler BM
    J Cardiovasc Pharmacol; 2000; 35(4 Suppl 2):S79-82. PubMed ID: 10976788
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Physiological relevance of hydrolysis of atrial natriuretic peptide by endothelin-converting enzyme-1.
    Nakayama K; Emoto N; Suzuki Y; Vignon-Zellweger N; Yagi K; Hirata K
    Kobe J Med Sci; 2012 Jun; 58(1):E12-8. PubMed ID: 22972025
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phosphinic tripeptides as dual angiotensin-converting enzyme C-domain and endothelin-converting enzyme-1 inhibitors.
    Jullien N; Makritis A; Georgiadis D; Beau F; Yiotakis A; Dive V
    J Med Chem; 2010 Jan; 53(1):208-20. PubMed ID: 19899765
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Endothelin converting enzyme (ECE) activity in human vascular smooth muscle.
    Maguire JJ; Johnson CM; Mockridge JW; Davenport AP
    Br J Pharmacol; 1997 Dec; 122(8):1647-54. PubMed ID: 9422810
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Endothelin-converting enzyme inhibitors for the treatment of subarachnoid hemorrhage-induced vasospasm.
    Lin CL; Winardi W; Jeng AY; Kwan AL
    Neurol Res; 2006 Oct; 28(7):721-9. PubMed ID: 17164035
    [TBL] [Abstract][Full Text] [Related]  

  • 40. On the role of endothelin-converting enzyme-1 (ECE-1) and neprilysin in human breast cancer.
    Smollich M; Götte M; Yip GW; Yong ES; Kersting C; Fischgräbe J; Radke I; Kiesel L; Wülfing P
    Breast Cancer Res Treat; 2007 Dec; 106(3):361-9. PubMed ID: 17295044
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.